# Sarcoma Oncology Center Reports 50% Partial Response Rate for DeltaRex-G at ESMO 2026

> Sarcoma Oncology Center presented DeltaRex-G data at ESMO 2026 showing a 50% partial response rate and 90% clinical benefit in 10 evaluable patients.

- Published: 2026-10-26T06:54:55+00:00
- Section: Research & Clinical Trials
- Author: News Desk
- URL: https://newsforagent.com/news/2026-10-26/sarcoma-oncology-center-deltarex-g-esmo-data
- Source: [EIN Presswire](https://www.einnews.com/pr_news/952070805/the-sarcoma-oncology-center-announces-promising-clinical-data-for-deltarex-g-gene-therapy-at-esmo-2026-madrid-spain)

## Key takeaways

- The Sarcoma Oncology Center reported a 50% partial response rate, or 5 of 10 evaluable patients, for DeltaRex-G at ESMO 2026 in Madrid.
- Median progression-free survival was 6.7 months for sarcomas and 7.8 months across all cancer types.
- Tumor biomarker screening of 332 samples found enhanced CCNG1 expression in 100% of samples.

The Sarcoma Oncology Center presented updated clinical data for its investigational gene therapy DeltaRex-G at ESMO 2026 in Madrid, showing a 50% partial response rate and a 90% clinical benefit rate among 10 evaluable patients. The Santa Monica, California center announced the findings in a release published by [EIN Presswire](https://www.einnews.com/pr_news/952070805/the-sarcoma-oncology-center-announces-promising-clinical-data-for-deltarex-g-gene-therapy-at-esmo-2026-madrid-spain).

## DeltaRex-G Results in Chemoresistant Solid Tumors

The data cover patients with Stage 4 chemoresistant, CCNG1-expressing solid tumors, and the center said the findings expand the drug's demonstrated efficacy profile to include ovarian cancer. Among evaluable patients, 5 of 10 showed a partial response, including one patient who received DeltaRex-G combined with FDA-approved drugs as a first-line treatment. The overall clinical benefit rate reached 9 of 10 patients, and no treatment-related adverse events above Grade 3 were reported.

Median progression-free survival was 6.7 months for sarcomas and 7.8 months across all cancer types. Median overall survival reached 18.7 months for sarcomas and 14.8 months across all pooled cancer types.

Tumor biomarker screening of 332 samples at the Sarcoma Oncology Center and Cancer Center of Southern California found enhanced CCNG1 expression in 100% of samples. Of those, 22% showed high expression, 39% medium-high, 35% medium-low and 4% low. Sarcomas made up 88.6% of the tested samples, with 2.7% invasive ductal carcinoma of breast, 0.9% pancreatic ductal adenocarcinoma and 7.8% other cancer types including serous ovarian adenocarcinoma.

"These results build upon previously reported improvements in progression-free and overall survival for patients facing aggressive, Stage 4 chemoresistant CCNG1-expressing cancers, now explicitly including ovarian cancer," said Dr. Sant P. Chawla, ESMO presenter and Director of the Sarcoma Oncology Center. "The high clinical benefit and response rates observed suggest that administering DeltaRex-G in combination with FDA-approved therapies as a first-line intervention would likely yield even better responses and survival benefits for patients with metastatic disease."

## Sarcoma Oncology Center's Research Background

According to [akta.pro company records](https://akta.pro/company-data), the [Sarcoma Oncology Center](https://akta.pro/company-profiles/003da2k/sarcoma-oncology-center) was founded in 1989 and is headquartered in Santa Monica, with a headcount range of 1 to 10. The center provides multi-disciplinary, experimental and advanced cancer care, and it says it pioneers novel clinical protocols and targeted therapies for sarcomas and solid tumors. DeltaRex-G, also known as DNG64-CAR-V, was invented by Drs. Erlinda M. Gordon and Frederick L. Hall as an investigational tumor-targeted gene therapy vector designed to inhibit the CCNG1 proto-oncogene pathway.

## DeltaRex-G's Next Steps

The Aveni Foundation, a non-profit organization dedicated to accelerating gene therapy development, is involved in the work, and the center's announcement directs further information to its [website](https://www.sarcomaoncology.com).

## Companies in this story

- [Sarcoma Oncology Center company profile](https://akta.pro/company-profiles/003da2k/sarcoma-oncology-center) · website: https://www.sarcomaoncology.com

---
News for Agent · https://newsforagent.com/llms.txt